Amifostine is a cytoprotective adjuvant used for reduction in the cumulative renal toxicity in patients with ovarian cancer and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. A phosphorothioate proposed as a radiation-protective agent.
- Mechanism
- Curator reviewed
The thiol metabolite is responsible for most of the cytoprotective and radioprotective properties of amifostine. It is readily taken up by cells where it binds to and detoxifies reactive metabolites of platinum and alkylating agents as well as scavenges free radicals. Other possible effects include inhibition of apoptosis, alteration of gene expression and modification of enzyme activity.
- Primary indication
- For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.Curator reviewed · 3 structured indications
- Formula / weight
- C5H15N2O3PS · 214.223 g/mol (avg)
- First approval
- Canada, 2000 · United States, 1995
- Also known as
- Aminopropylaminoethyl thiophosphate · Ethiofos
- Code names
- WR-2721 · YM-08310
- Brand names
Resolves to
JKOQGQFVAUAYPM-UHFFFAOYSA-NSMILESNCCCNCCSP(O)(O)=OWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Amifostine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account